Companies · Biotechnology

X-Vax Technology, Inc.

JUPITER · Biotechnology

Diligence memoA one-page analyst read on X-Vax Technology, Inc. — recommendation, valuation, rhythm, risks.
$56.6M
Total raised · real
2
Rounds
0.1×
Latest step-up
Top 17%
Sector rank · raised
Series C
Latest stage · inferred · Fri Sep 28 2018 00:00:00 GMT+0000 (Coordinated Universal Time)

X-Vax Technology, Inc. looks fair against its niche peers and is dormant on financing cadence.

Synthesized from the figures below est. — every claim rests on a number shown on this page. Valuation uses the biotech sector profile.

Analyst read est. — computed against this company's niche peers in the same era. Inputs shown; not a quoted figure.

Fair
  • Modeled value is 1.13× the median modeled value of Series C Biotechnology companies in 2016–2018 (41 peers) — value vs value, same stage and era.
  • Within the normal band (113% of peer median) for its niche.
Dormant
  • Last raise 7.8 yr ago; this sector typically re-raises about every 14 months.
  • Silent for over 3× the sector's normal cadence.
Leadership

No named principal in this company's public records yet — see all operators below.

Explore how these operators interlock with other companies in the operator network.

Where it sits in Biotechnology

X-Vax Technology, Inc. is one of 4293 Biotechnology companies tracked from JUPITER. By capital raised it ranks in the upper tier (ahead of 84% of sector peers), and among the largest by modeled valuation est..

Ranking is computed against this company's own sector cohort — reported capital is fact; valuation tiers are modeled.

As reported in public records reported — not modeled.

US
Jurisdiction
Rule 506(b)
Reg D exemption
9
Investors (latest)
2015
Year incorporated
2018-09-28
First sale
Amount raised vs valuation, by round

Solid bars are reported offering amounts reported; hatched bars are the modeled post-money valuation est. — both on one shared scale so you can read raise-vs-worth at each round directly. Use the toggles to overlay data labels and the niche-peer / market average value lines.

Amount raised · realModeled valuation · estCumulative funded · real
$0$1.3B$2.5B$3.8B$5.0BPre-Seed · 2016-09-06 Raised $100K (real) Modeled valuation $5.5M (est)$100K$5.5MPre-Seed2016Series C · 2018-09-28 Raised $47M (real) Modeled valuation $1.9B (est)$47M$1.9BSeries C2018Series C · 2018-09-28 Raised $42M (real) Modeled valuation $1.7B (est)$42M$1.7BSeries C2018Series B · 2018-09-28 Raised $39M (real) Modeled valuation $1.6B (est)$39M$1.6BSeries B2018Series C · 2018-09-28 Raised $56M (real) Modeled valuation $2.3B (est)$56M$2.3BSeries C2018Series A · 2018-09-28 Raised $6.5M (real) Modeled valuation $237M (est)$6.5M$237MSeries A2018+$47M+$42M+$39M+$56M+$6.5MCumulative $191M

The line shows cumulative reported funding over the period; + labels show new capital added between points when there is room. Toggle on-bar figures, plus the niche-peer and market averages, to read this company against its cohort. Benchmarks are modeled medians.

Financing ladder & sequence gaps
Pre-Seed$100K · 2016
Series C$46.7M · 2018no Seed / Series A / Series B on file
Series C extension$42.2M · 2018
Bridge · Series C-stage$39.3M · 2018smaller follow-on
Series C extension$56.5M · 2018
Bridge · Series C-stage$6.5M · 2018smaller follow-on

Stages are modeled from round size (public records carry no series label). No record for: Seed — the company may have raised it under a different exemption, merged it into an adjacent record, or skipped it. Sequence completeness: 80%.

Modeled valuation trajectory
$2.3B
Base estimate est.
$174.7M
Conservative case
$6.1B
Upside case
$376.4M
Modeled post-money

Round size and date are reported; the stage label is inferred from round size (latest is Series Ca $40M–$100M round). Valuation is modeled from stage benchmarks scaled by the biotech sector profile. Directional, not a quoted figure.

Pre-Seed · modeled $5.5M · 2016-09-062016Series C · modeled $1.9B · 2018-09-28Series C · modeled $1.7B · 2018-09-28Series B · modeled $1.6B · 2018-09-28Series C · modeled $2.3B · 2018-09-28Series A · modeled $236.8M · 2018-09-282018
Model inputs · modeled:benchmark-stage-stepup-v1
15%
Dilution assumption
Implied ownership sold in the financing.
62%
Survival probability
46% low · 72% high
1.46×/yr
Annual markup
1.68×/yr upside case
6.0 yr
Elapsed time used
7.8 yr actual, capped for stale marks
biotech
Sector profile
Adjusts growth and survival by industry.
Financing rhythm
5 mo
Avg between rounds
$27.5M/yr
Capital velocity
9.8 yr
On record since
2016
First round
6
Rounds on file
How it compares to the market

Benchmarked against 4293 companies in Biotechnology. Each bar is a median (the middle company, not an average — outliers don't skew it). Two yardsticks: real money raised (reported on Form D) and modeled value (our estimate est.). These are whole-sector medians across all stages, except the per-stage row.

Total raised — vs sector median (real $, all stages) 7.9× above median
This company$56.6M
Sector median$7.2M
Latest round — vs other Series C rounds in sector (real $, this stage) 0.1× of median
This company$6.5M
Sector median$46.5M
Modeled value — vs sector median (estimate, all stages) 36× above median
This company$2.3B
Sector median$64.2M

Raised more than 84% of sector peers (real $). Modeled value above 95% of peers (estimate).

Niche peers — same stage & era

A tighter cohort than the sector chart above — only companies at the same stage (Series C) that last raised in the same ~3-year era, ranked by modeled value est. (not money raised). This is the exact set the analyst read compares against, so a like-for-like cohort is what makes "over/under-valued" meaningful. This company ranks #15 of 41.

This companyCohort peer
$1.0B$10.0B$10.0M$100.0M$1.0BCapital raised (log)Genesis Biopharma, Inc · Series C Raised $131.5M · modeled $4.1B (est)Alder Biopharmaceuticals Inc · Series C Raised $100.0M · modeled $4.1B (est)Ideaya Biosciences, Inc. · Series C Raised $111.4M · modeled $3.9B (est)Stoke Therapeutics, Inc. · Series C Raised $90.8M · modeled $3.7B (est)4D Molecular Therapeutics Inc · Series C Raised $108.6M · modeled $3.7B (est)Sutro Biopharma Inc · Series C Raised $85.4M · modeled $3.5B (est)Evelo Biosciences, Inc. · Series C Raised $131.5M · modeled $3.3B (est)Celularity Inc. · Series C Raised $117.7M · modeled $3.2B (est)Codiak BioSciences, Inc. · Series C Raised $107.5M · modeled $3.1B (est)Arcturus Therapeutics Ltd. · Series C Raised $67.8M · modeled $2.8B (est)Celldex Therapeutics, Inc. · Series C Raised $64.5M · modeled $2.6B (est)Micell Technologies Inc · Series C Raised $62.1M · modeled $2.5B (est)X-Vax Technology, Inc. (this company) Raised $56.6M · modeled $2.3B (est)X-Vax Technology, Inc.
CompanyStageRaised · realValue · estvs peer med.
Genesis Biopharma, IncSeries C$131.5M$4.1B2.00×
Alder Biopharmaceuticals IncSeries C$100.0M$4.1B2.00×
Ideaya Biosciences, Inc.Series C$111.4M$3.9B1.88×
Stoke Therapeutics, Inc.Series C$90.8M$3.7B1.80×
4D Molecular Therapeutics IncSeries C$108.6M$3.7B1.80×
Sutro Biopharma IncSeries C$85.4M$3.5B1.71×
Evelo Biosciences, Inc.Series C$131.5M$3.3B1.63×
Celularity Inc.Series C$117.7M$3.2B1.55×
Codiak BioSciences, Inc.Series C$107.5M$3.1B1.53×
Arcturus Therapeutics Ltd.Series C$67.8M$2.8B1.36×
Celldex Therapeutics, Inc.Series C$64.5M$2.6B1.25×
Micell Technologies IncSeries C$62.1M$2.5B1.24×
X-Vax Technology, Inc. this companySeries C$56.6M$2.3B1.13×
Full financing history

Stage is inferred from round size est., not reported on the filing — a round's dollar size maps to a bucket: Pre-Seed <$1.0M · Seed $1.0M–$4.0M · Series A $4.0M–$15M · Series B $15M–$40M · Series C $40M–$100M · Series D+ $100M–$400M · Growth/Late >$400M.

StageAmount · realAnnouncedPost-money · estValue · estConf.
Pre-Seed$100K2016-09-06$556K$5.5M85%
Series C$46.7M2018-09-28$311.2M$1.9B90%
Series C$42.2M2018-09-28$281.2M$1.7B90%
Series B$39.3M2018-09-28$218.2M$1.6B90%
Series C$56.5M2018-09-28$376.4M$2.3B90%
Series A$6.5M2018-09-28$29.8M$236.8M90%
What happened at each round

Step-up, pace versus the sector's normal cadence, and revenue/exemption moves — read straight from the reported round facts reported.

  1. Pre-Seed$100K2016-09-06
    • First recorded raise — entered as Pre-Seed.
    • 1 investor on this round.
  2. Series C$46.7M2018-09-28
    • Raised again after 25 mo — slower than the ~14 mo sector norm.
    • Round 466.8× larger than the prior — scaling up.
    • 269 investors on this round.
  3. Series C$42.2M2018-09-28
    • Filed alongside the prior round (same month) — likely a tranche or amendment.
    • Round roughly the size of the prior one.
    • 242 investors on this round.
  4. Series B$39.3M2018-09-28
    • Filed alongside the prior round (same month) — likely a tranche or amendment.
    • Round roughly the size of the prior one.
    • 230 investors on this round.
  5. Series C$56.5M2018-09-28
    • Filed alongside the prior round (same month) — likely a tranche or amendment.
    • Round 1.4× larger than the prior — scaling up.
    • 306 investors on this round.
  6. Series A$6.5M2018-09-28
    • Filed alongside the prior round (same month) — likely a tranche or amendment.
    • Round 8.6× smaller than the prior — bridge or down round.
    • 9 investors on this round.
Intelligence
2019 ~Q1
Modeled next raise · ~5mo cadence
$6.5M
Modeled next size est.range $6.5M$10.5M
0.1×
Last step-up
$27.5M/yr
Capital velocity

Predictive signals are modeled est. from this company's own cadence and step-up, plus sector benchmarks — directional, not advice. Peer set and a CSV export live in your analyst workspace.

Key people & operators

Officers, directors and promoters named in this company's public recordsreported — the people who run it (not its investors). "Also runs" counts come from name-matching across all records, so verify before acting.

PersonRoleAlso runsTied since
Isaac Blech13 other2016-09
Robert Ruffolo7 other2016-09
Brian D. Finn3 other2018-09
Roger J. Pomerantz3 other2018-09
Roger Pomerantz3 other2016-09
Ian T. Clark1 other2018-09
Jacob Uittenbogaard1 other2018-09
Matthew R. Stober1 other2018-09
Roger A. Jeffs1 other2018-09
William A Haseltine1 other2016-09
Andreas Eggert2018-09
Clare Kahn2018-09
Isaac T. Blech2018-09
Richard Kenney2018-09
Robert R. Ruffolo2018-09
Ulf Wiinberg2018-09
Registry & provenance

X-Vax Technology, Inc. is an official record sourced from the U.S. Securities and Exchange Commission (SEC). U.S. data is aggregated from SEC Form D filings.

United States
Country of record
US
Jurisdiction
1682900
SEC CIK
2015
Incorporated
Similar companies

Nearest neighbours across the whole database — matched on sector, stage and capital scale, and on shared operators (officers or directors named at both companies in public filings). A discovery shortlist, not a valuation cohort — verify before acting, the same way modeled figures are directional.

CompanySectorStageRaised · realValue · estWhy similar
Alveo Technologies Inc.BiotechnologySeries C$63.6M$503.5Mnetwork1 shared operator · same sector · same stage
Istari Oncology, Inc.BiotechnologySeries C$48.6M$1.4Bnetwork1 shared operator · same sector · same stage
Sapience Therapeutics, Inc.BiotechnologySeries B$30.8M$317.9Mnetwork2 shared operators · same sector
Elicio Therapeutics, Inc.BiotechnologySeries B$105.3M$392.9Mnetwork2 shared operators · same sector
Elucida Oncology, Inc.BiotechnologySeries B$117.1M$255.6Mnetwork2 shared operators · same sector
Viracta Therapeutics, INC.BiotechnologySeries C$164.6M$2.1Bnetwork1 shared operator · same sector · same stage
Centrexion Therapeutics CorpBiotechnologySeries C$202.0M$35.3Mnetwork1 shared operator · same sector · same stage
Angion Biomedica Corp.BiotechnologySeries B$52.0M$48.4Mnetwork1 shared operator · same sector
Semantically similar

Matched by meaning, not labels — a local language model reads each company's name, sector and description and ranks the closest in that learned space. This catches look-alikes that cross sector boundaries; the structured list above explains its matches, this one trusts the text. Directional, like every modeled signal here.

CompanySectorStageValue · estMatch
X-Biomedical Inc.BiotechnologyPre-Seed$23.5M93%
Xeno Biosciences Inc.BiotechnologySeries A$16.4M91%
Vaxess Technologies, Inc.BiotechnologySeries C$270.2M90%
Xenetic Biosciences, Inc.BiotechnologySeries A$5.9M90%
CancerVAX, Inc.BiotechnologyPre-Seed$7.2M90%
X-Rase RD Development, LLCBiotechnologySeed$41.4M89%
Xcell Biosciences, Inc.BiotechnologySeries B$8.3M89%
XenoTherapeutics CorpBiotechnologySeed$39.0M88%
Frequently asked
How much funding has X-Vax Technology, Inc. raised?
X-Vax Technology, Inc. has raised approximately $56.6M in disclosed capital across 2 recorded financing rounds, aggregated from public filings.
What is X-Vax Technology, Inc.'s estimated valuation?
Provath's modeled valuation for X-Vax Technology, Inc. is approximately $2.3B (modeled range $174.7M–$6.1B). This is an algorithmic estimate derived from round sizes and same-niche peers — not a quoted or reported figure.
What funding stage is X-Vax Technology, Inc. at?
X-Vax Technology, Inc.'s latest modeled financing stage is Series C. Its most recent recorded round closed around Fri Sep 28.
What does X-Vax Technology, Inc. do and where is it based?
X-Vax Technology, Inc. operates in the Biotechnology sector, based in JUPITER.
Explore related

See where X-Vax Technology, Inc. sits in the wider market — its sector, location and stage cohorts, each with their own leaderboards and capital-flow timelines.

Is this your company?

If you work at X-Vax Technology, Inc., claim this profile or suggest a correction. We aggregate from public filings, so help us keep your description, website and links accurate.

Is this your company? Update your profile or add contact details — and choose exactly who can reach you. Reviewed before anything is published.